报价延迟最少15分钟:2025/07/20 16:58 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.36 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.65/1.19
|
|
企业价值
383.95M
|
| 资产负债 |
|
每股账面净值
-3.64
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 16:58 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy. |
